Compare Bristol-Myers Squibb Co (BMY) vs Eos Energy Enterprises Inc (EOSE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Eos Energy Enterprises Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.57 (market cap $132.45B), while Eos Energy Enterprises Inc trades at $4.27 (market cap $1.47B). The key difference: Bristol-Myers Squibb Co is far larger — about 90.1× Eos Energy Enterprises Inc's market cap, and Bristol-Myers Squibb Co pays a 3.89% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals.
| BMY | EOSE | |
|---|---|---|
Market Cap | $132.45B | $1.47B |
Sector | Health | Energy |
52-Week High | $65.89 | $19.19 |
52-Week Low | $42.60 | $3.14 |
Enterprise Value | $166.44B | $1.81B |
Dividend Yield | 3.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.72, up 0.89% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a net income margin of 18.87% and ROE of 46.7%, though debt levels have risen. Recent news highlights a $2.3 billion manufacturing investment and merger speculation with AstraZeneca, driving investor interest.
BMY presents a mixed outlook: valuation metrics like P/E of 14.26 appear attractive, and analyst consensus targets $68.56. However, risks include patent expirations, high debt, and volatile cash flows. The stock's near-term performance hinges on merger developments and execution of growth initiatives amid competitive pressures.
Eos Energy Enterprises (EOSE) trades at $4.15, up 5.33% today, but faces significant financial challenges with a net income margin of -246.76% and negative cash flow from operations. The company reported record Q2 2026 revenue but missed earnings expectations with a $1.20 per share loss. Technical indicators show a mixed picture with bullish overall signals but bearish moving averages, while analyst sentiment remains cautious with 70% hold ratings.
Despite revenue growth potential in the energy storage market, EOSE carries substantial risk due to persistent losses, high debt-to-asset ratio of 91.87%, and ongoing shareholder litigation. The consensus price target of $7.75 suggests upside potential, but investors should weigh the company's financial instability against its growth prospects in the competitive battery storage sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →
